9 May 2024
Scancell Holdings plc
("Scancell" or the "Company")
Scancell announces multiple upcoming presentations at the 21st CIMT Annual Meeting
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that multiple abstracts have been accepted for an oral and as poster presentations at the 21st Association for Cancer Immunotherapy CIMT Annual Meeting being, taking place in Mainz, Germany, on 15-17 May 2024.
Impressive clinical data of SCIB1, supported by functional T cell responses to the TRP2 and gp100 peptides which can be detected in patients post vaccination, will be presented by Head of Translational Research, Dr Samantha Paston. The posters will show the isolation of specific TCRs that recognise post translationally modified peptides and the application of Anti-Sialyl-di-Lewis-a as a CAR-T. Professor Lindy Durrant, Chief Executive Officer of Scancell. "We are thrilled to have a robust presence at this year's CIMT meeting. These presentations are a reflection of Scancell's high quality science and expertise in developing innovative immunotherapies to address unmet needs in cancer."
CIMT is Europe's largest meeting focused on cancer immunotherapy research and development. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.
Oral Presentation details are as follows:
Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma
Session: Short talk session VI
Date and Time: Thursday, 17th May 2024 between 10.30am-12.00pm
Location: Rheingoldhalle Congress Center Mainz
Abstract No: 139
Speaker: Dr Samantha Paston
Authors: Samantha Paston, Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Robert Miller, Gaëlle Cane, Joseph Chadwick, Sabaria Shah, Victoria Brentville, Rachael Metheringham, Georgia Goodhew, Fayaz Master, Lindy Durrant.
Poster Presentation details are as follows:
Title: Isolation and characterisation of TCRs that recognise Citrullinated and Homocitrullinated post translationally modified peptides
Session Poster session I
Date and Time Wednesday, 15th May 2024 between 3.00pm-5.30pm
Location Rheingoldhalle Congress Center Mainz
Abstract No: 34
Authors: Samantha Paston, Ruhul Choudhury, Sabaria Shah, Gaëlle Cane, Joseph Chadwick, Rachael Metheringham, Fayaz Master, Rebecca Herbertson, Lindy Durrant.
Title: Anti-Sialyl-di-Lewisa CAR T cells for effective tumor therapy of gastrointestinal tumor
Session Poster session I
Date and Time Wednesday, 15th May 2024 between 3.00pm-5.30pm
Location Rheingoldhalle Congress Center Mainz
Abstract No: 5
Authors: I. Charles, K. Cook, G. Cane, B. Kaira, A. Skinner, A. Wright, M. Vankemmelbeke, R. Metheringham, V. Brentville, L. Durrant
The posters will be made available on the Company's website following the conference at https://www.scancell.co.uk/antibody-publications
| For further information, please contact: | |
| | |
| Scancell Holdings plc | +44 (0) 20 3709 5700 |
| Dr Jean-Michel Cosséry, Non-Executive Chairman | |
| Professor Lindy Durrant, CEO | |
| | |
| Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7710 7600 |
| Nicholas Moore/Samira Essebiyea | |
| Nick Harland (Corporate Broking)
| |
| WG Partners LLP (Joint Broker) David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby
| +44 (0) 20 3705 9330
|
| Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
| Freddy Crossley/Emma Earl (Corporate Finance) | |
| Rupert Dearden (Corporate Broking) | |
| | |
| ICR Consilium | +44 (0) 20 3709 5700 |
| Mary-Jane Elliott/Angela Gray/Lindsey Neville |
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab® ).
For further information about Scancell, please visit: https://www.scancell.co.uk/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
